SanofiMEX:SAN1N 72 Gross Margin % is 71.75% as of Dec. 2025, which is 4% above its 10-year median of 68.94. GuruFocus rates MEX:SAN1N with a GF Score™ of 72/100 and a GF Value™ of MXN2,212.65 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 938 Drug Manufacturers companies, Sanofi ranks better than 84.75% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Sanofi's Gross Profit for the
six
months ended in Dec. 2025 was MXN383,876 Mil. Sanofi's Revenue for the
six
months ended in Dec. 2025 was MXN535,005 Mil. Therefore, Sanofi's Gross Margin % for the quarter that ended in Dec. 2025 was 71.75%.
The historical rank and industry rank for Sanofi's Gross Margin % or its related term are showing as below:
MEX:SAN1N'
s Gross Margin % Range Over the Past 10 Years
Min: 67.46 Med: 68.94 Max: 72.07
Current: 72.07
During the past 13 years, the highestGross Margin % of Sanofi was 72.07%. The lowest was 67.46%. And the median was 68.94%.
MEX:SAN1N's Gross Margin % is ranked better than 84.75% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs MEX:SAN1N: 72.07
Sanofi had a gross margin of 71.75% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Sanofi was 1.10% per year.
Sanofi (MEX:SAN1N) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sanofi had a gross margin of 71.75% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sanofi Gross Margin % Related Terms
Sanofi Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sanofi's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SAN1N vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Sanofi's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sanofi's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sanofi (MEX:SAN1N) has a Gross Margin % of 71.75% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Sanofi and its competitors. This is near median its historical median of 68.94. Over the past decade, Sanofi's Gross Margin % has ranged from 67.46 to 72.07. According to the industry distribution chart, Sanofi ranks #143 out of 938 companies in the Drug Manufacturers industry, placing it in the top 15.2%.
Is Sanofi's Gross Margin % too high?
Sanofi's current Gross Margin % of 71.75% is near median its 10-year median of 68.94. Over the past 10 years, this metric has ranged from a low of 67.46 to a high of 72.07. The Drug Manufacturers industry median Gross Margin % is 48.44. Sanofi's value of 71.75% is 48.1% above this industry median. Based on the distribution chart, Sanofi ranks #143 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #143 out of 938 companies for Gross Margin %. This places Sanofi in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.44. Sanofi's value of 71.75% is 48.1% above this benchmark. Historically, Sanofi's own Gross Margin % has ranged from 67.46 to 72.07 over the past decade. While the company's 10-year median is 68.94 vs. the industry median of 48.44, Sanofi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi's current Gross Margin % of 71.75% is 48.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sanofi and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current Gross Margin % is 71.75%, which is near median its own 10-year median of 68.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (MEX:SAN1N) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,212.65, compared to a current price of MXN1,525.85 — trading 31% below its estimated fair value. The current Gross Margin % is 71.75%, which is near median its 10-year median of 68.94 and 48.1% above the Drug Manufacturers industry median of 48.44. Sanofi's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sanofi (MEX:SAN1N), the current Gross Margin % is 71.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (MEX:SAN1N) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of MXN1,525.85 is trading 31% below its estimated GF Value™ of MXN2,212.65.
GuruFocus considers Sanofi to be Possible Value Trap.
Key valuation signals for MEX:SAN1N:
Gross Margin %: 71.75% (near median its 10-year median of 68.94)
GF Value™: MXN2,212.65 vs. price of MXN1,525.85 (31% below fair value)
Industry Position: 48.1% above the Drug Manufacturers median (#143 of 938)
No single metric tells the full story. See the MEX:SAN1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
72GF Score
Get the complete analysis for MEX:SAN1N
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SAN1N has been successfully added to your 
